Allon Therapeutics Inc.
NPCUF
$0.0001
$0.000.00%
OTC PK
| 03/31/2013 | 12/31/2012 | 09/30/2012 | 06/30/2012 | 03/31/2012 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -2.66% | -4.48% | -21.42% | -21.41% | -27.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.60% | -14.72% | -30.19% | -21.98% | -21.05% |
| Operating Income | 27.60% | 14.72% | 30.19% | 21.98% | 21.05% |
| Income Before Tax | -4.65% | -15.96% | 29.56% | 20.44% | 19.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.65% | -15.96% | 29.56% | 20.44% | 19.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.65% | -15.96% | 29.56% | 20.44% | 19.51% |
| EBIT | 27.60% | 14.72% | 30.19% | 21.98% | 21.05% |
| EBITDA | 27.50% | 15.09% | 31.09% | 22.70% | 21.82% |
| EPS Basic | 31.82% | 23.65% | 48.32% | 34.76% | 27.80% |
| Normalized Basic EPS | 51.82% | 42.36% | 48.79% | 35.27% | 27.84% |
| EPS Diluted | 31.82% | 23.65% | 48.32% | 34.76% | 27.80% |
| Normalized Diluted EPS | 51.82% | 42.36% | 48.79% | 35.27% | 27.84% |
| Average Basic Shares Outstanding | 52.86% | 50.78% | 43.57% | 24.18% | 12.56% |
| Average Diluted Shares Outstanding | 52.86% | 50.78% | 43.57% | 24.18% | 12.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |